Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer

Abstract

Background Although the docetaxel, 5-fluorouracil, and cisplatin triplet has yielded significant improvements in time to progression, overall survival, and overall response rate, the high incidence of severe adverse events limits the use of the docetaxel, 5-fluorouracil, and cisplatin triplet. To overcome this limitation, we evaluated the efficacy and safety of the combination of docetaxel, oxaliplatin, and S-1 for the treatment of metastatic gastric cancer. Methods Chemotherapy-naive patients with pathologically proven unresectable recurrent or metastatic gastric adenocarcinoma were assessed for eligibility. Docetaxel at 52.5 mg/m 2 and oxaliplatin at 105 mg/m 2 were administered intravenously on day 1, and S-1 was administered orally at 80 mg/m 2 on days 1-14 of every 21-day cycle.Results Forty-four patients (median age 54.5 years) were enrolled. All patients had metastatic disease. A total of 340 cycles of chemotherapy were administered (median of eight cycles per patient; range 1-36 cycles). Toxicities were evaluated in 43 patients, and the responses were evaluated in 40 patients. Major toxicities included grade 3/4 neutropenia (37.2 %) and leukopenia (27.9 %). The overall response rate was 54.5 % [95 % confidence interval (CI) 40.1-68.3 %] in the intention-to-treat population. The median progression-free survival and overall survival were 7.6 months (95 % CI 6.2-9.0 months) and 12.0 months (95 % CI 6.9-17.2 months), respectively. Conclusion These data suggest that the docetaxel, oxaliplatin, and S-1 combination regimen is effective and relatively well tolerable, and it seems to have potential to be a reasonable therapeutic strategy in patients with metastatic or recurrent gastric cancer.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11

“…Our group conducted a phase II study that evaluated a combination of docetaxel, oxaliplatin, and S-1 (DOS) in patients with metastatic gastric cancer [23]. The DOS regimen consisted of 52.5 mg/m 2 docetaxel and 105 mg/m 2 oxaliplatin on day 1 and 80 mg/m 2 S-1 on days 1-14 every 3 weeks.…”

Effect of docetaxel‑loaded lipid microbubble in combination with ultrasound‑triggered microbubble destruction on the growth of a gastric cancer cell line

“…Therefore, UTMD combined with DLLD may serve as an effective tumor-targeting strategy. Docetaxel (DOC), a well-known anti-cancer drug, has been demonstrated to be effective for the treatment of advanced gastric cancer (25)(26)(27). In the present study, lipid microbubbles containing DOC were prepared, and the effects of DOC-loaded microbubbles combined with UTMD on the growth of a gastric cell line were investigated.…”

High expression of Wls is associated with lymph node metastasis and advanced TNM stage in gastric carcinomas

“…Another reason is the metastasis, which is the most critical determinant of gastric carcinoma associated death. The prognosis of gastric carcinoma is still poor since most patients present with advanced or metastatic disease, even though the surgery, postoperative chemo‐radiotherapy, immunotherapy, targeted therapy collaborative mode have improved the survival rate . Exploring the specific molecular markers for early diagnosis and detection of lymph node metastasis is critical to improve the survival of patients with gastric carcinoma …”

“…The prognosis of gastric carcinoma is still poor since most patients present with advanced or metastatic disease, even though the surgery, postoperative chemo-radiotherapy, immunotherapy, targeted therapy collaborative mode have improved the survival rate. [3][4][5][6] Exploring the specific molecular markers for early diagnosis and detection of lymph node metastasis is critical to improve the survival of patients with gastric carcinoma. [7][8][9][10][11] The Wnt pathway was initially characterized for its role in the cell-cell communication that controls a multitude of fundamental patterning processes during animal development.…”